

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/000563-2023>

Tender

NHS Framework Agreement for the supply of Ranibizumab for the NHS in England

NHS England

F02: Contract notice

Notice identifier: 2023/S 000-000563

Procurement identifier (OCID): ocds-h6vhtk-0395f7

Published 9 January 2023, 3:19pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Mary-Jo Pryor

Email

mary-jo.pryor@nhs.net

Country

United Kingdom

Region code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Framework Agreement for the supply of Ranibizumab for the NHS in England

Reference number

C123966

II.1.2) Main CPV code

- 33690000 - Various medicinal products

II.1.3) Type of contract

Supplies

II.1.4) Short description

The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England.

Anti Veg-F medicines are currently used in the treatment of:

- a. neovascular (wet) age-related macular degeneration (AMD);
- b. visual impairment due to diabetic macular oedema (DME/DMO);
- c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and
- d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

II.1.5) Estimated total value

Value excluding VAT: £120,000,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKE - Yorkshire and the Humber

Main site or place of performance

NHS England

II.2.4) Description of the procurement

The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England.

Anti Veg-F medicines are currently used in the treatment of:

- a. neovascular (wet) age-related macular degeneration (AMD);
- b. visual impairment due to diabetic macular oedema (DME/DMO);
- c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and
- d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £120,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 April 2023

End date

31 March 2024

This contract is subject to renewal

Yes

Description of renewals

An option to extend for a further period of 12 months. i.e. the total possible framework agreement duration is 24 months.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

10 February 2023

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 1 May 2023

IV.2.7) Conditions for opening of tenders

Date

10 February 2023

Local time

5:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: Yes

Estimated timing for further notices to be published: 8 months

VI.4) Procedures for review

VI.4.1) Review body

NHS England

Quarry House, Quarry Hill

Leeds

LS2 7UE

Country

United Kingdom

Internet address

<https://www.england.nhs.uk/>